These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34561288)

  • 1. Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.
    Decroo T; Aung KJM; Hossain MA; Gumusboga M; Ortuno-Gutierrez N; De Jong BC; Van Deun A
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34561288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response.
    Lange C; Kherabi Y; Guglielmetti L; Duarte R; Günther G;
    Clin Microbiol Infect; 2024 Sep; 30(9):1207-1208. PubMed ID: 38901496
    [No Abstract]   [Full Text] [Related]  

  • 3. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
    Guglielmetti L; Le Dû D; Veziris N; Caumes E; Marigot-Outtandy D; Yazdanpanah Y; Robert J; Fréchet-Jachym M;
    Eur Respir J; 2016 Aug; 48(2):582-5. PubMed ID: 27338196
    [No Abstract]   [Full Text] [Related]  

  • 4. Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They?
    Bastard M; Guglielmetti L; Huerga H; Hayrapetyan A; Khachatryan N; Yegiazaryan L; Faqirzai J; Hovhannisyan L; Varaine F; Hewison C
    Am J Respir Crit Care Med; 2018 Nov; 198(9):1228-1231. PubMed ID: 29969054
    [No Abstract]   [Full Text] [Related]  

  • 5. Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.
    Bouton TC; de Vos M; Ragan EJ; White LF; Van Zyl L; Theron D; Horsburgh CR; Warren RM; Jacobson KR
    PLoS One; 2019; 14(10):e0223308. PubMed ID: 31622366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.
    Kwon YS; Jeon D; Kang H; Yim JJ; Shim TS
    Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 33093123
    [No Abstract]   [Full Text] [Related]  

  • 7. A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis.
    Deng G; Fu L
    Lancet Infect Dis; 2024 Sep; 24(9):940-941. PubMed ID: 38768618
    [No Abstract]   [Full Text] [Related]  

  • 8. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
    Lessem E; Cox V; Furin J
    Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 10. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TB Alliance regimen development for multidrug-resistant tuberculosis.
    Murray S; Mendel C; Spigelman M
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):38-41. PubMed ID: 28240571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
    Schnippel K; Ndjeka N; Maartens G; Meintjes G; Master I; Ismail N; Hughes J; Ferreira H; Padanilam X; Romero R; Te Riele J; Conradie F
    Lancet Respir Med; 2018 Sep; 6(9):699-706. PubMed ID: 30001994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
    Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY
    Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug-resistant tuberculosis and bedaquiline.
    Salfinger M; Somoskövi A
    N Engl J Med; 2014 Dec; 371(25):2435-6. PubMed ID: 25517715
    [No Abstract]   [Full Text] [Related]  

  • 17. Multidrug-resistant tuberculosis and bedaquiline.
    Diacon AH; Lounis N; Dannemann B
    N Engl J Med; 2014 Dec; 371(25):2436. PubMed ID: 25517714
    [No Abstract]   [Full Text] [Related]  

  • 18. Bedaquiline: a new drug approved for treatment of multidrug-resistant tuberculosis.
    Deoghare S
    Indian J Pharmacol; 2013; 45(5):536-7. PubMed ID: 24130398
    [No Abstract]   [Full Text] [Related]  

  • 19. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence that pyrazinamide resistance is acquired after fluoroquinolone resistance.
    Cobelens F; Gebhard A; van den Hof S
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):282. PubMed ID: 26792486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.